Dainippon Sumitomo Pharma has a large product portfolio in the CNS area and has adopted a multifaceted research approach to target better treatments for psychiatric conditions, including schizophrenia, depression, anxiety and cognitive disorders. Dainippon Sumitomo Pharma is endeavoring to increase the number of early-stage CNS research projects by promoting early-stage research, and forming alliances with domestic and overseas research institutions, including universities and biotech companies with promising technologies.
Emer Leahy, president and CEO of PsychoGenics, said: “By combining Dainippon Sumitomo’s and PsychoGenics’s complementary strengths and expertise we are confident we will be able to identify treatments for neuropsychiatric disorders.”